News
LXRX
2.400
-9.09%
-0.240
Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech
Seeking Alpha · 11h ago
Weekly Report: what happened at LXRX last week (0622-0626)?
Weekly Report · 1d ago
Health Care had the best week vs. the S&P 500 on record
Seeking Alpha · 4d ago
Weekly Report: what happened at LXRX last week (0615-0619)?
Weekly Report · 06/22 09:37
Weekly Report: what happened at LXRX last week (0608-0612)?
Weekly Report · 06/15 09:37
Weekly Report: what happened at LXRX last week (0601-0605)?
Weekly Report · 06/08 09:35
Lexicon presents new sotagliflozin Type 1 diabetes subgroup analysis at ADA 2026 sessions
PUBT · 06/03 12:05
Lexicon Pharmaceuticals’ Earnings Call Highlights Milestone-Fueled Surge
TipRanks · 06/02 00:10
Weekly Report: what happened at LXRX last week (0525-0529)?
Weekly Report · 06/01 09:37
Lexicon Pharmaceuticals management to join Jefferies Global Healthcare Conference fireside chat
PUBT · 05/28 12:32
SA analyst upgrades/downgrades: SMCI, AMZN, SFM, LXRX
Seeking Alpha · 05/27 17:05
Lexicon Pharmaceuticals: Uncertainty Clouds The Bull Case (Rating Downgrade)
Seeking Alpha · 05/26 20:15
Weekly Report: what happened at LXRX last week (0518-0522)?
Weekly Report · 05/25 09:39
Weekly Report: what happened at LXRX last week (0511-0515)?
Weekly Report · 05/18 09:39
Lexicon Pharmaceuticals to present at H.C. Wainwright BioConnect Investor Conference
PUBT · 05/12 12:31
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 05/11 17:05
Lexicon Pharma Price Target Raised to $3.10/Share From $2.30 by Citigroup
Dow Jones · 05/11 15:19
Lexicon Pharma Is Maintained at Buy by Citigroup
Dow Jones · 05/11 15:19
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1
Benzinga · 05/11 15:10
Lexicon price target raised to $3.10 from $2.30 at Citi
TipRanks · 05/11 11:01
More
Webull provides a variety of real-time LXRX stock news. You can receive the latest news about Lexicon Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About LXRX
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.